Similar articles for PMID: 23223392

Year	Number of Results
1947	1
1950	1
1962	2
2001	2
2002	3
2003	5
2004	3
2005	2
2006	5
2007	4
2008	7
2009	3
2010	8
2011	8
2012	15
2013	16
2014	12
2015	21
2016	19
2017	23
2018	26
2019	17
2020	16
2021	31
2022	14
2023	7
2024	0

1

Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment.

Sandström M, Garske-Román U, Granberg D, Johansson S, Widström C, Eriksson B, Sundin A, Lundqvist H, Lubberink M. Sandström M, et al. J Nucl Med. 2013 Jan;54(1):33-41. doi: 10.2967/jnumed.112.107524. Epub 2012 Dec 7. J Nucl Med. 2013. PMID: 23223392 Free article. Clinical Trial.

2

Effect of calculation method on kidney dosimetry in ¹⁷⁷Lu-octreotate treatment.

Heikkonen J, Mäenpää H, Hippeläinen E, Reijonen V, Tenhunen M. Heikkonen J, et al. Acta Oncol. 2016 Sep-Oct;55(9-10):1069-1076. doi: 10.1080/0284186X.2016.1182642. Epub 2016 May 24. Acta Oncol. 2016. PMID: 27219529

3

Personalized ¹⁷⁷Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study.

Del Prete M, Buteau FA, Beauregard JM. Del Prete M, et al. Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1490-1500. doi: 10.1007/s00259-017-3688-2. Epub 2017 Mar 31. Eur J Nucl Med Mol Imaging. 2017. PMID: 28361189

4

Prospective observational study of ¹⁷⁷Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity.

Garske-Román U, Sandström M, Fröss Baron K, Lundin L, Hellman P, Welin S, Johansson S, Khan T, Lundqvist H, Eriksson B, Sundin A, Granberg D. Garske-Román U, et al. Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):970-988. doi: 10.1007/s00259-018-3945-z. Epub 2018 Mar 1. Eur J Nucl Med Mol Imaging. 2018. PMID: 29497803 Free PMC article.

5

Kidney dosimetry during ¹⁷⁷Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance.

Sandström M, Garske-Román U, Johansson S, Granberg D, Sundin A, Freedman N. Sandström M, et al. Acta Oncol. 2018 Apr;57(4):516-521. doi: 10.1080/0284186X.2017.1378431. Epub 2017 Sep 18. Acta Oncol. 2018. PMID: 28920501

6

A dosimetry procedure for organs-at-risk in ¹⁷⁷Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours.

Marin G, Vanderlinden B, Karfis I, Guiot T, Wimana Z, Reynaert N, Vandenberghe S, Flamen P. Marin G, et al. Phys Med. 2018 Dec;56:41-49. doi: 10.1016/j.ejmp.2018.11.001. Epub 2018 Nov 22. Phys Med. 2018. PMID: 30527088 Free article.

7

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate.

Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, Teunissen JJ, de Jong M, van Lom K, de Herder WW, Kwekkeboom DJ. Forrer F, et al. Eur J Nucl Med Mol Imaging. 2009 Jul;36(7):1138-46. doi: 10.1007/s00259-009-1072-6. Epub 2009 Feb 27. Eur J Nucl Med Mol Imaging. 2009. PMID: 19247653 Free PMC article. Clinical Trial.

8

Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.

Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, Tritschler S, Stief CG, Kopka K, Haberkorn U, Bartenstein P, Böning G. Delker A, et al. Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):42-51. doi: 10.1007/s00259-015-3174-7. Epub 2015 Aug 29. Eur J Nucl Med Mol Imaging. 2016. PMID: 26318602

9

Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[¹⁷⁷Lu]Lu-DOTA-TATE PRRT in Normal Organs and Tumor Lesions in Patients of Metastatic Neuroendocrine Tumors: Comparison with No-Carrier-Added [¹⁷⁷Lu]Lu-DOTA-TATE and the Trend with Multiple Cycles.

Kamaldeep, Loharkar S, Das T, Basu S, Banerjee S. Kamaldeep, et al. Cancer Biother Radiopharm. 2022 Apr;37(3):214-225. doi: 10.1089/cbr.2021.0340. Epub 2021 Dec 15. Cancer Biother Radiopharm. 2022. PMID: 34910891

10

Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.

Bergsma H, Konijnenberg MW, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, Franssen GJ, van Eijck CH, Krenning EP, Kwekkeboom DJ. Bergsma H, et al. Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):453-63. doi: 10.1007/s00259-015-3193-4. Epub 2015 Sep 30. Eur J Nucl Med Mol Imaging. 2016. PMID: 26419852 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

234 results

Results by year